REGN241206C810000
- 0.45
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
RBC Capital Remains a Buy on Regeneron (REGN)
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Wolfe Research Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,150
Regeneron Pharma Initiated at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $800 to $1,195
Regeneron Pharma Is Maintained at Buy by Truist Securities
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,135
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195